Anavex Life Sciences Corp.AVXLNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P3
Near historical low
vs 5Y Ago
-1.2x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -36.17% |
| Q3 2025 | -26.76% |
| Q2 2025 | 0.68% |
| Q1 2025 | -5.30% |
| Q4 2024 | -9.60% |
| Q3 2024 | -2.17% |
| Q2 2024 | 21.40% |
| Q1 2024 | 12.03% |
| Q4 2023 | -13.68% |
| Q3 2023 | -2.16% |
| Q2 2023 | -2.60% |
| Q1 2023 | -12.51% |
| Q4 2022 | 6.02% |
| Q3 2022 | 22.73% |
| Q2 2022 | 7.77% |
| Q1 2022 | -0.60% |
| Q4 2021 | -7.64% |
| Q3 2021 | 4.55% |
| Q2 2021 | 33.38% |
| Q1 2021 | -15.20% |
| Q4 2020 | 29.82% |
| Q3 2020 | -9.22% |
| Q2 2020 | 11.10% |
| Q1 2020 | -4.66% |
| Q4 2019 | 34.77% |
| Q3 2019 | -18.19% |
| Q2 2019 | -5.27% |
| Q1 2019 | 6.42% |
| Q4 2018 | 29.60% |
| Q3 2018 | 47.03% |
| Q2 2018 | -7.62% |
| Q1 2018 | 20.44% |
| Q4 2017 | -29.77% |
| Q3 2017 | 66.78% |
| Q2 2017 | -7.73% |
| Q1 2017 | 22.05% |
| Q4 2016 | -52.93% |
| Q3 2016 | 274.42% |
| Q2 2016 | 6.26% |
| Q1 2016 | -6.29% |